MA33323B1 - Thérapie adjuvante de cancer - Google Patents

Thérapie adjuvante de cancer

Info

Publication number
MA33323B1
MA33323B1 MA34342A MA34342A MA33323B1 MA 33323 B1 MA33323 B1 MA 33323B1 MA 34342 A MA34342 A MA 34342A MA 34342 A MA34342 A MA 34342A MA 33323 B1 MA33323 B1 MA 33323B1
Authority
MA
Morocco
Prior art keywords
cancer
adjuvant therapy
adjuvant
compositions
provides methods
Prior art date
Application number
MA34342A
Other languages
Arabic (ar)
English (en)
Inventor
Gwendolyn Fyfe
Eric Hedrick
Robert D Mass
Norman Wolmark
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of MA33323B1 publication Critical patent/MA33323B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fertilizers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention porte sur des procédés et des compositions comprenant des anticorps anti-VEGF pour une utilisation dans une thérapie adjuvante de cancer.
MA34342A 2009-04-20 2010-04-20 Thérapie adjuvante de cancer MA33323B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26
PCT/US2010/031740 WO2010123891A1 (fr) 2009-04-20 2010-04-20 Thérapie adjuvante de cancer

Publications (1)

Publication Number Publication Date
MA33323B1 true MA33323B1 (fr) 2012-06-01

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34342A MA33323B1 (fr) 2009-04-20 2010-04-20 Thérapie adjuvante de cancer

Country Status (19)

Country Link
US (1) US20100266589A1 (fr)
EP (1) EP2421558A1 (fr)
JP (1) JP2012524083A (fr)
KR (1) KR20120096401A (fr)
CN (1) CN102458467A (fr)
AR (1) AR076344A1 (fr)
AU (1) AU2010239368A1 (fr)
BR (1) BRPI1006438A2 (fr)
CA (1) CA2759030A1 (fr)
CL (1) CL2011002610A1 (fr)
CO (1) CO6450651A2 (fr)
CR (1) CR20110553A (fr)
IL (1) IL215764A0 (fr)
MA (1) MA33323B1 (fr)
MX (1) MX2011010955A (fr)
RU (1) RU2011147051A (fr)
SG (1) SG175289A1 (fr)
TW (1) TW201106969A (fr)
WO (1) WO2010123891A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
SG181938A1 (en) 2009-12-25 2012-07-30 Pharmalogicals Res Pte Ltd Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
WO2013035824A1 (fr) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド Séparation de cellules souches cancéreuses
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
EP2772268B8 (fr) * 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Molécule spécifique des cellules souches cancéreuses
JP6312659B2 (ja) * 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
RU2015104001A (ru) * 2012-08-07 2016-09-27 Дженентек, Инк. Комбинированная терапия для лечения глиобластомы
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
EP2914263A4 (fr) 2012-11-02 2016-04-27 Pharmacyclics Inc Thérapie adjuvante par inhibiteur de kinase de la famille tec
WO2014190311A2 (fr) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Réparation de mésappariement défectueux et bénéfice tiré du bevacizumab pour le cancer du colon
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CA2942528A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics Inc. Mutations de phospholipase c gamma 2 et associees aux resistances
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
WO2017042318A1 (fr) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptide de chémérine pour le traitement de la cachexie provoquée par le cancer
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
IL132240A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
MY183404A (en) * 2006-12-19 2021-02-18 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2125016A2 (fr) * 2007-02-01 2009-12-02 Genetech, Inc. Polychimiothérapie avec inhibiteurs de l'angiogenèse
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Also Published As

Publication number Publication date
AU2010239368A1 (en) 2011-11-10
IL215764A0 (en) 2012-01-31
JP2012524083A (ja) 2012-10-11
RU2011147051A (ru) 2013-05-27
TW201106969A (en) 2011-03-01
US20100266589A1 (en) 2010-10-21
CO6450651A2 (es) 2012-05-31
CA2759030A1 (fr) 2010-10-28
MX2011010955A (es) 2012-04-02
AR076344A1 (es) 2011-06-01
CN102458467A (zh) 2012-05-16
BRPI1006438A2 (pt) 2016-09-27
WO2010123891A1 (fr) 2010-10-28
CR20110553A (es) 2012-01-23
SG175289A1 (en) 2011-11-28
EP2421558A1 (fr) 2012-02-29
KR20120096401A (ko) 2012-08-30
CL2011002610A1 (es) 2012-04-09

Similar Documents

Publication Publication Date Title
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA32126B1 (fr) Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MY166776A (en) Humanised anti-ctla4 antibodies
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MX2010005080A (es) Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
MX2012014080A (es) Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
CU24058B1 (es) Antagonistas de pcsk9
MX347020B (es) Anticuerpo contra el csf-1r.
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EP2111408A4 (fr) Compositions et procédés comprenant des microarn pour traiter une néoplasie
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
GB0515353D0 (en) Food
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)